Triumeq generic
Triumeq is an anti-retroviral drug owned by Viiv Healthcare. The drug, which contains Abacavir Sulfate, Dolutegravir Sodium, and Lamivudine, was first introduced to the market on August 22, 2014. Triumeq has a total of 4 patents.
When will Triumeq generic be available?
The last patent for Triumeq is set to expire on June 8, 2030, which will make it possible for generics of Triumeq to enter the market thereafter.
Triumeq uses
The main use of Triumeq is in the treatment of HIV. Its active ingredients, Abacavir Sulfate, Dolutegravir Sodium, and Lamivudine, work together to inhibit the growth of the virus and prevent it from multiplying, thus helping to control or slow down the progression of the disease.
Triumeq patent expiration
Triumeq holds several patents, the latest of which, titled 'Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates', expires on June 8, 2030. This indicates that the availability of Triumeq generics could be possible after this date. Below are the details of the patents: